VTGN VistaGen Therapeutics

VistaGen Therapeutics to Participate in Baird’s 2021 Global Healthcare Conference

VistaGen Therapeutics to Participate in Baird’s 2021 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in Baird’s 2021 Global Healthcare Conference, including a fireside chat with Shawn Singh, Chief Executive Officer, on Tuesday, September 14 at 12:10 p.m. Pacific Time and one-on-one meetings throughout the two-day conference.

A live webcast of VistaGen’s presentation will be accessible through the page of the Investors section of the Company’s website at .

About VistaGen

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit  and connect with VistaGen on , , and .

VistaGen Company Contacts

Media:

Mark McPartland

Phone: (650) 577-3606

Email:

Investors:

Mark Flather

Phone: (650) 577-3617

Email:  

 



EN
08/09/2021

Underlying

VTGNVistaGen Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VistaGen Therapeutics

 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen to Participate in the Maxim Group Healthcare Virtual Conferen...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in the Healthcare Virtual Conference presented by Maxim Group LLC taking place June 20 – 22, 2023 virtually on the M-Vest platform. Maxim Group Healthcare Virtual Conference 2023 Fireside Chat Date and Time: Thursday, June 22, 2023 at 1:30 p.m. Eastern T...

June 16, 2023 1 EN
 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen Announces European Patent Office Intention to Grant New PH80 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued an intention to grant a patent for the treatment of migraine by nasal administration of PH80 nasal spray, one of the Company’s five rapid-onset investigational neuroactive pherine therapeutics. The patent claims also include treatment administered at the onset of migraine symptoms an...

June 13, 2023 1 EN
 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen Announces Positive Results from Exploratory Phase 2A Study of...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the Company’s five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory Phase 2A study for the acute treatment of hot flashes (vasomotor symptoms) in women diagnosed with menopausal hot flashes. The randomized, double-blind, placebo-contro...

June 7, 2023 1 EN
 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen to Present at Jefferies 2023 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference taking place June 7 – 9, 2023 in New York City, NY. Jefferies 2023 Global Healthcare Conference Details Fireside Chat Date and Time: Friday, June 9 at 9:30 a.m. Eastern Time Location: M...

June 6, 2023 1 EN
 PRESS RELEASE
Free
VTGN VistaGen Therap...

Vistagen Announces Stockholder-Approved Reverse Stock Split

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty unanimously approved by its Board of Directors. Vistagen common stock will begin trading on a split-adjusted basis at the opening of trading on the Nasdaq Capital Market on Wednesday, June 7, 20...

June 6, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch